专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1993016725A1 EARLY ANTIGEN FOR AUTOIMMUNE DIABETES 审中-公开
标题翻译：早产儿自发性糖尿病
公开(公告)号：WO1993016725A1
公开(公告)日：1993-09-02
申请号：PCT/US1993001716
申请日：1993-02-25
申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD ... , IMMULOGIC PHARMACEUTICAL CORPORATION
发明人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD ... , IMMULOGIC PHARMACEUTICAL CORPORATION , FATHMAN, C., Garrison , PABORSKY, Lisa , GELBER, Cohava
IPC分类号： A61K39/00
CPC分类号： C07K14/705 , A61K38/00 , G01N33/5091
摘要： Antigens associated with the beta islet cells that activate T-cell populations in inducing type I diabetes are disclosed. These antigens are useful in diagnosis and therapy of type I diabetes.
摘要翻译：公开了与诱导I型糖尿病激活T细胞群体的β岛细胞相关的抗原。这些抗原可用于I型糖尿病的诊断和治疗。

2. 发明公开

EP0627934A1 EARLY ANTIGEN FOR AUTOIMMUNE DIABETES 失效
标题翻译：早期抗原自身免疫，糖尿病反。
公开(公告)号：EP0627934A1
公开(公告)日：1994-12-14
申请号：EP93907049.0
申请日：1993-02-25
申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY , IMMULOGIC PHARMACEUTICAL CORPORATION
发明人： FATHMAN, C., Garrison , PABORSKY, Lisa , GELBER, Cohava
IPC分类号： G01N33 , A61K39 , A61P37 , C07K14 , C07K16 , C12N1 , C12N5 , C12N15 , C12P21 , A61K38
CPC分类号： C07K14/705 , A61K38/00 , G01N33/5091
摘要： L'invention se rapporte à des antigènes associés à des cellules ilôts beta qui activent les populations de lymphocytes T en induisant le diabète de type I. Ces antigènes peuvent être utilisés dans le diagnostic et la thérapie du diabète de type I.

3. 发明申请

WO2001085943A1 ANERGY ASSOCIATED GENES 审中-公开
标题翻译：神经相关基因
公开(公告)号：WO2001085943A1
公开(公告)日：2001-11-15
申请号：PCT/US2001/015385
申请日：2001-05-11
申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
发明人： FORD, Gregory, S. , BLOOM, Debra , FATHMAN, C., Garrison
IPC分类号： C12N15/12
CPC分类号： C07K14/4705 , C12N2799/027
摘要： Isolated nucleic acid compositions and sequences of anergy associated genes are provided, including the novel GRAIL gene. Expression of these genes is unregulated during the early stages of induction of anergy. The murine GRAIL sequence is shown to attenuate IL-2 transcription in T cells during response to antigenic stimulation. The identification of genes involved in the induction of anergy is useful in the evaluation of the pathophysiology or immunotherapy of cancer, autoimmune disease, and transplant rejection. Genetic sequences involved in anergy induction are useful markers in the evaluation of specific immunotherapies. Functional characterization of genes involved in anergy induction allows the elucidation of the mechanism(s) of T cell anergy, including the transcriptional blockade of IL-2, which may be manipulated to regulate T cell responses in human disease. The signalling pathways involving GRAIL are of significant interest in the identification of drugs that either block or upregulate the function(s) of GRAIL.
摘要翻译：提供分离的核酸组合物和无反应相关基因的序列，包括新型GRAIL基因。在诱导无反应的早期阶段，这些基因的表达是不受调节的。显示鼠GRAIL序列在抗原刺激反应期间减弱T细胞中的IL-2转录。诱导无反应性的基因的鉴定可用于癌症，自身免疫疾病和移植排斥的病理生理学或免疫治疗的评价。涉及无能诱导的遗传序列是评估特异性免疫疗法中的有用标志物。涉及无能诱导的基因的功能表征允许阐明T细胞无反应的机制，包括IL-2的转录阻断，其可被操纵以调节人类疾病中的T细胞应答。涉及GRAIL的信号通路对于鉴定可阻断或上调GRAIL功能的药物具有重要意义。

4. 发明申请

WO1997026325A1 COMPOSITIONS AND THEIR USES FOR TRANSFER OF DOWN-REGULATORY GENES INTO CELLS ASSOCIATED WITH INFLAMMATORY RESPONSES 审中-公开
标题翻译：组合物及其用于将下调基因转移到与炎症反应相关的细胞中的用途
公开(公告)号：WO1997026325A1
公开(公告)日：1997-07-24
申请号：PCT/US1997001178
申请日：1997-01-16
申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
发明人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY , FATHMAN, C., Garrison , ROTHBARD, Jonathan , STROBER, Samuel , ENGLEMAN, Edgar, G. , NOLAN, Garry
IPC分类号： C12N05/00
CPC分类号： C12N15/86 , A61K38/1841 , A61K38/2026 , A61K38/2066 , A61K48/00 , C07K14/525 , C12N2740/13043 , C12N2800/108 , C12N2830/002 , C12N2840/203
摘要： Genes encoding down-regulatory molecules are transferred into inflammatory cells, including T lymphocytes and dendritic cells. Local inflammatory responses are suppressed by the targeted delivery of such genes. The down-regulatory molecules can be secreted cytokines or cytokine blockers that act extracellularly to suppress inflammation. Alternatively, the down-regulatory molecules act intracellularly to disrupt internal signaling and activation in disease associated lymphocytes. Specificity of targeting is achieved by ex vivo gene transfer into disease associated cells, or by the use of retroviral gene transfer vectors having specific targeting envelope proteins. The use of inducible promoters allows local secretion of the cytokines and limits the effect of down-regulatory T cells to sites of antigen recognition.
摘要翻译：编码下调分子的基因被转移到炎症细胞中，包括T淋巴细胞和树突状细胞。局部炎症反应被这种基因靶向递送所抑制。下调分子可以分泌细胞因子或细胞因子阻断剂，其在细胞外作用以抑制炎症。或者，下调调节分子在细胞内作用，以破坏疾病相关淋巴细胞中的内部信号传导和活化。靶向的特异性通过离体基因转移到疾病相关细胞中，或通过使用具有特异性靶向包膜蛋白的逆转录病毒基因转移载体来实现。诱导型启动子的使用允许局部分泌细胞因子并限制下调T细胞对抗原识别位点的影响。

5. 发明申请

WO2009108341A1 TRANSIENT EXPRESSION OF IMMUNOMODULATORY POLYPEPTIDES FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASE, ALLERGY AND TRANSPLANT REJECTION 审中-公开
标题翻译：用于预防和治疗自身免疫性疾病，过敏反应和移植物排斥反应的免疫抑制多聚体的瞬时表达
公开(公告)号：WO2009108341A1
公开(公告)日：2009-09-03
申请号：PCT/US2009/001232
申请日：2009-02-27
申请人： ARGOS THERAPEUTICS, INC. , THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY , NICOLETTE, Charles , FATHMAN, C., Garrison , CREUSOT, Remi
发明人： NICOLETTE, Charles , FATHMAN, C., Garrison , CREUSOT, Remi
IPC分类号： C12N15/00
CPC分类号： C12N15/86 , A61K38/2026 , A61K48/00 , A61K48/005 , A61K2035/124 , C12N5/0639 , C12N2501/23 , C12N2501/24 , C12N2501/25 , C12N2510/00 , C12N2740/15043
摘要： A method is provided for treating or preventing an undesired immune response in a patient, comprising: administering to said patient, cells that transiently express, and/or that are transfected with mRNA encoding, one or more polypeptides selected from the group consisting of an IL-4 receptor agonist, an IFN-γ receptor antagonist, an IFN-α receptor antagonist, an IL-12 receptor antagonist, an IL-23 receptor antagonist, and a TNF antagonist. Preferably, the cells selectively accumulate in one or more secondary lymphoid tissues at or proximate to the site of the undesired immune response. Related compositions are provided. The methods and compositions are useful for the treatment or prevention of undesired immune responses including, but not limited to, transplant rejection, autoimmune disease, allergy and immune responses directed against therapeutic compositions.
摘要翻译：提供了一种用于治疗或预防患者不期望的免疫应答的方法，其包括：向所述患者施用瞬时表达的细胞和/或用编码一种或多种选自IL -4受体激动剂，IFN- 受体拮抗剂，IFN-α受体拮抗剂，IL-12受体拮抗剂，IL-23受体拮抗剂和TNF拮抗剂。优选地，细胞在不期望的免疫应答的位点处或其附近选择性地累积在一个或多个次级淋巴组织中。提供相关的组合物。所述方法和组合物可用于治疗或预防不期望的免疫应答，包括但不限于针对治疗组合物的移植排斥反应，自身免疫疾病，变态反应和免疫应答。

6. 发明申请

WO2003028441A1 GENE THERAPY FOR THE PREVENTION OF AUTOIMMUNE DISEASE 审中-公开
标题翻译：用于预防自发性疾病的基因治疗
公开(公告)号：WO2003028441A1
公开(公告)日：2003-04-10
申请号：PCT/US2002/031760
申请日：2002-10-02
申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY , FATHMAN, C., Garrison
发明人： FATHMAN, C., Garrison
IPC分类号： A01K63/00
CPC分类号： C07K16/2809 , A61K38/2026 , A61K39/0008 , A61K48/00 , A61K2035/122 , A61K2035/124 , A61K2039/505 , A61K2039/5154
摘要： Autoimmune disease is treated by the delivery of a suppressive agent to the site of disease. Delivery is accomplished by introducing an expression vector encoding the suppressive agent into cells targeted for such sites, and administering the genetically modified cells to the patient. Suppressive agents of particular interest include IL-4; and anti-CD3 antibodies, particularly single chain anti-CD3 antibodies. Cells of interest for delivery include T cells and T cell hybridomas, where the T cell antigen receptor recognizes epitopes associated with the autoimmune disease. Alternatively, dendritic cells are used as delivery vectors.
摘要翻译：通过将抑制剂递送至疾病部位来治疗自身免疫性疾病。通过将编码抑制剂的表达载体导入到针对这些位点的细胞中，并将该基因修饰的细胞施用于患者来实现递送。特别感兴趣的抑制剂包括IL-4; 和抗CD3抗体，特别是单链抗CD3抗体。用于递送的感兴趣的细胞包括T细胞和T细胞杂交瘤，其中T细胞抗原受体识别与自身免疫疾病相关的表位。或者，树突状细胞用作递送载体。

7. 发明公开

EP2254998A1 TRANSIENT EXPRESSION OF IMMUNOMODULATORY POLYPEPTIDES FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASE, ALLERGY AND TRANSPLANT REJECTION 有权
标题翻译：瞬间表达的免疫调节多肽为防止及治疗自身免疫性疾病，过敏和移植
公开(公告)号：EP2254998A1
公开(公告)日：2010-12-01
申请号：EP09713841.6
申请日：2009-02-27
申请人： Argos Therapeutics, Inc. , The Board of Trustees of The Leland Stanford Junior University
发明人： NICOLETTE, Charles , FATHMAN, C., Garrison , CREUSOT, Remi
IPC分类号： C12N15/00
CPC分类号： C12N15/86 , A61K38/2026 , A61K48/00 , A61K48/005 , A61K2035/124 , C12N5/0639 , C12N2501/23 , C12N2501/24 , C12N2501/25 , C12N2510/00 , C12N2740/15043
摘要： A method is provided for treating or preventing an undesired immune response in a patient, comprising: administering to said patient, cells that transiently express, and/or that are transfected with mRNA encoding, one or more polypeptides selected from the group consisting of an IL-4 receptor agonist, an IFN-gamma receptor antagonist, an IFN-alpha receptor antagonist, an IL-12 receptor antagonist, an IL-23 receptor antagonist, and a TNF antagonist. Preferably, the cells selectively accumulate in one or more secondary lymphoid tissues at or proximate to the site of the undesired immune response. Related compositions are provided. The methods and compositions are useful for the treatment or prevention of undesired immune responses including, but not limited to, transplant rejection, autoimmune disease, allergy and immune responses directed against therapeutic compositions.

8. 发明授权

EP2254998B1 TRANSIENT EXPRESSION OF IMMUNOMODULATORY POLYPEPTIDES FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASE, ALLERGY AND TRANSPLANT REJECTION 有权
标题翻译：瞬间表达的免疫调节多肽为防止及治疗自身免疫性疾病，过敏和移植
公开(公告)号：EP2254998B1
公开(公告)日：2015-12-23
申请号：EP09713841.6
申请日：2009-02-27
申请人： Argos Therapeutics, Inc. , The Board of Trustees of the Leland Stanford Junior University
发明人： NICOLETTE, Charles , FATHMAN, C., Garrison , CREUSOT, Remi
IPC分类号： C12N15/00
CPC分类号： C12N15/86 , A61K38/2026 , A61K48/00 , A61K48/005 , A61K2035/124 , C12N5/0639 , C12N2501/23 , C12N2501/24 , C12N2501/25 , C12N2510/00 , C12N2740/15043
摘要： A method is provided for treating or preventing an undesired immune response in a patient, comprising: administering to said patient, cells that transiently express, and/or that are transfected with mRNA encoding, one or more polypeptides selected from the group consisting of an IL-4 receptor agonist, an IFN-gamma receptor antagonist, an IFN-alpha receptor antagonist, an IL-12 receptor antagonist, an IL-23 receptor antagonist, and a TNF antagonist. Preferably, the cells selectively accumulate in one or more secondary lymphoid tissues at or proximate to the site of the undesired immune response. Related compositions are provided. The methods and compositions are useful for the treatment or prevention of undesired immune responses including, but not limited to, transplant rejection, autoimmune disease, allergy and immune responses directed against therapeutic compositions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式